Recent developments include SCWorx regaining compliance with Nasdaq's periodic reporting listing standard in November 2024 and ongoing efforts to regain compliance with Nasdaq's minimum bid price rule following delisting in April 2026.

• SCWorx regained compliance with Nasdaq's periodic reporting listing standard as of November 21, 2024 [N8].
• The company was delisted from Nasdaq in April 2026 due to failure to meet minimum bid price requirements but appealed and was granted continued listing subject to conditions including a reverse stock split [S1].
• SCWorx effected a 1-for-15 reverse stock split in April 2026 to regain compliance with Nasdaq’s minimum bid price rule [S1].
• As of June 30, 2026, SCWorx reported quarterly revenue of $706,049 and a net loss of $120,954, with EPS of -$1.35 basic and diluted [S2].
• Liquidity ratios at 2026-06-30 included a current ratio of 2.19 and a cash ratio of 0.12, with cash and equivalents of $91,436 [S2].

SCWorx’s comprehensive healthcare data platform addresses critical interoperability challenges faced by hospitals, offering a suite of integrated software modules that improve operational efficiency and financial performance. The company’s SaaS model and multi-year contracts provide recurring revenue visibility. Its large data warehouse and advanced analytics capabilities enable benchmarking and actionable insights, which can drive customer retention and expansion. The company’s recent compliance with Nasdaq’s reporting standards and efforts to regain listing compliance demonstrate operational discipline. Strategic partnerships and direct sales channels support client acquisition across the U.S. market. The company’s ability to automate complex processes such as RFPs, contract management, and rebate tracking positions it well to capture value in a growing healthcare IT market focused on cost containment and data-driven decision-making.

SCWorx operates in a competitive and rapidly evolving healthcare IT market with competitors ranging from internal hospital departments to large and small specialized vendors. The company has reported net losses and negative earnings per share, indicating ongoing challenges in achieving profitability. Its recent delisting from Nasdaq due to minimum bid price non-compliance and the need for a reverse stock split highlight market valuation and liquidity challenges. Regulatory scrutiny related to past COVID-19 test kit sales may pose reputational and legal risks. The company’s reliance on multi-year contracts and SaaS delivery requires sustained client retention and successful integration of acquired businesses. Failure to meet Nasdaq’s continued listing requirements or to raise additional capital could impact operations and market access.

SCWorx’s moat is based on its specialized healthcare data platform that creates a Single Source of Truth for hospital product data, enabling interoperability across supply chain, clinical, and billing systems. The company’s extensive data warehouse with over 12 million items, combined with its big data analytics and benchmarking capabilities, provides differentiated value to healthcare providers. The SaaS delivery model and multi-year contracts create recurring revenue streams and customer stickiness. Additionally, the company’s ability to integrate acquired businesses and automate complex processes such as contract and rebate management adds to its competitive positioning. Barriers to entry in this niche include the technological complexity of healthcare data normalization, the need for proven interoperability across multiple hospital systems, and the establishment of a broad client base and distribution channels. However, competition from larger, more established firms and smaller specialized vendors remains a challenge.

• Nasdaq Listing Compliance Risk: SCWorx was delisted from Nasdaq in April 2026 due to failure to meet minimum bid price requirements and must demonstrate compliance by August 28, 2026, including through a reverse stock split. Failure to maintain listing could reduce liquidity and market visibility.
• Financial Performance Risk: The company reported a net loss and negative EPS for the quarter ended June 30, 2026, indicating ongoing challenges in achieving profitability and positive cash flow.
• Regulatory and Legal Risk: SCWorx faced SEC charges in 2022 related to misleading investors about COVID-19 test kit sales, which may pose reputational and legal risks.
• Competitive Risk: The healthcare data management market is competitive with larger companies and specialized vendors, which may have greater resources, brand recognition, and product breadth.
• Operational Risk: The company’s business depends on successful integration of acquired businesses, client retention, and maintaining technological sophistication to meet evolving healthcare IT needs.

• SCWorx Corp. is a Delaware corporation headquartered in Middleton, Massachusetts.
• The company provides data content and services focused on repair, normalization, and interoperability of healthcare provider information, along with big data analytics for the healthcare industry.
• SCWorx’s software platform enables healthcare providers to improve data flow between supply chain, electronic medical records (EMR), clinical systems, and patient billing functions.
• The company’s solutions include modules for Item Master File repair and automation, EMR management, Charge Description Master management, contract management, RFP automation, integration of acquired businesses, rebate management, big data analytics, and data warehousing.
• SCWorx’s software is delivered primarily via SaaS hosted on AWS or RackSpace, typically under three-to-five-year contracts.
• Clients are mainly U.S.-based hospitals and health systems, acquired through direct sales and strategic partnerships.
• The company competes with purchasing departments, large and small companies offering item master normalization, and software providers in benchmarking and analytics.
• Barriers to entry include technological sophistication, proven product, client base, interoperability, and capital for development and marketing.
• SCWorx had a data warehouse exceeding 12 million items and offers peer comparison reporting and real-time analytics.
• Financial snapshot as of 2026-06-30 shows quarterly revenue of $706,049 and a net loss of $120,954.
• Basic and diluted EPS for the quarter ended 2026-06-30 were -$1.35 per share.
• Liquidity ratios at 2026-06-30 include a current ratio of 2.19 and a cash ratio of 0.12, with cash and equivalents of $91,436.
• The company was delisted from Nasdaq in April 2026 due to failure to meet minimum bid price requirements but appealed and was granted continued listing subject to conditions.
• SCWorx effected a 1-for-15 reverse stock split in April 2026 to regain compliance with Nasdaq’s minimum bid price rule.
• The company must demonstrate compliance with Nasdaq’s minimum bid price rule by achieving a closing bid price of at least $1.00 per share for 20 consecutive trading days by August 28, 2026.
• SCWorx regained compliance with Nasdaq’s periodic reporting listing standard as of November 21, 2024.
• The company has faced SEC charges related to misleading investors about the sale of COVID-19 test kits in 2022.
• SCWorx’s business model and financials are summarized from the latest available SEC filings and Nasdaq news sources for informational purposes only.